JP will join and present on a panel exploring arbitration in the life sciences sector. As the sector continues to experience rapid growth, so does the number of related arbitrations. Many pharma and biotech projects are highly complex, span many years, and involve numerous stakeholders, providing fertile ground for disputes. The panel will explore why international arbitration is well suited to resolve licensing, joint-venture, and co-marketing disputes that accompany these projects.